Researchers in Newcastle have played a leading role in bringing personalised medicine into routine NHS care for people living with primary biliary cholangitis (PBC), a long-term autoimmune liver disease.

People with PBC were usually treated using a standard approach with the same medicine offered to most patients. Researchers recognised that patients with PBC do not all have the same clinical needs. This highlighted the need for a more personalised approach that could identify patients at greatest risk and ensure they received the most appropriate treatment at the right time.

Impact at a glance

  • Developed and implemented personalised treatment pathways for people with PBC;
  • Created the UK-PBC Risk Score and a novel patented blood test to identify patients at higher risk;
  • Supported the introduction of obeticholic acid into routine clinical practice across the NHS and internationally;
  • Led the first national audit of PBC care in partnership with the PBC Foundation;
  • Identified the first new therapy for cholestatic itch in 20 years;
  • Extended research into cognitive symptoms, informing new clinical trials in both PBC and Parkinson's disease;
  • Improved outcomes and quality of life for patients through targeted, evidence-based care.

Identifying patients at risk

Newcastle researchers lead the UK-PBC platform, a UK-wide consortium of hospitals, universities and patient groups, including the PBC Foundation.

Supported by funding from the Medical Research Council Stratified Medicine programme and the NIHR Biomedical Research Centre (BRC): Newcastle, the consortium has developed clinical tools to identify patients at higher risk of disease progression.

These innovations include the UK-PBC Risk Score, a predictive tool available as an iPhone app, and a novel blood test that has since been patented. Together, these tools help clinicians identify patients who may benefit from earlier intervention or more intensive treatment, enabling a more personalised treatment pathway.

 

Bringing new treatments into clinical practice

Working with industry partners, our researchers have helped introduce so called "step-up" therapies into clinical practice, when stronger treatment is required. In partnership with the PBC Foundation, the team also carried out the first national audit of PBC care to assess how effectively these new treatment approaches were being used and how widely they had been adopted.

A key example is obeticholic acid, a second-line treatment for PBC. The therapy received accelerated approval from the US Food and Drug Administration (FDA) in 2016, followed by NICE approval in 2017. It is now used across the NHS and healthcare systems internationally.

 

Addressing symptoms

Alongside improving treatment for the disease itself, Newcastle researchers have developed new approaches to managing the life-altering symptoms of PBC.

This work was made possible through the development of the PBC-40, a unique disease-specific quality of life measure. This questionnaire helps researchers and clinicians understand how PBC affects patients and evaluate whether new treatments are improving their quality of life.

Through a jointly funded project between the NIHR BRC: Newcastle and industry partners, researchers identified the first new therapy for itch associated with cholestatic liver disease in 20 years. This therapy has since progressed to a Phase 3 clinical trial led by Newcastle.

 

Extending research to improve understanding of cognitive symptoms

More recently, BRC-funded research has explored new MRI approaches to understanding brain function in people with PBC.

This work has led to a clinical trial investigating the effects of obeticholic acid on cognitive symptoms, including problems with memory and concentration, in people with both PBC and Parkinson's disease. The research links closely with our Dementia, Mental Health and Neurodegeneration theme and is helping to improve understanding of cognitive symptoms across different conditions.

 

Improving outcomes for patients in the UK and beyond

This programme of research has helped transform the management of primary biliary cholangitis, moving care away from a single treatment approach and towards personalised care based on individual patient needs.

The work has led to new tools for identifying patients at high risk of disease progression, supported the introduction of new treatments into routine practice, improved the management of symptoms that affect quality of life, and opened new areas of research into cognitive health.

As a result, patients with PBC in the UK and internationally now have access to more personalised treatment options and improved care throughout their disease journey.

 

Linked publications

  • The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines

    The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines

    Journal: BMJ Gut

    Author: Hirschfield et al.

    Summary: Primary biliary cholangitis (formerly known as primary biliary cirrhosis, PBC) is an autoimmune liver disease in which a cycle of immune mediated biliary epithelial cell injury, cholestasis and progressive fibrosis can culminate over time in an end-stage biliary cirrhosis. Both genetic and environmental influences are presumed relevant to disease initiation. PBC is most prevalent in women and those over the age of 50, but a spectrum of disease is recognised in adult patients globally; male sex, younger age at onset (<45) and advanced disease at presentation are baseline predictors of poorer outcome. As the disease is increasingly diagnosed through the combination of cholestatic serum liver tests and the presence of antimitochondrial antibodies, most presenting patients are not cirrhotic and the term cholangitis is more accurate. Disease course is frequently accompanied by symptoms that can be burdensome for patients, and management of patients with PBC must address, in a life-long manner, both disease progression and symptom burden. Licensed therapies include ursodeoxycholic acid (UDCA) and obeticholic acid (OCA), alongside experimental new and re-purposed agents. Disease management focuses on initiation of UDCA for all patients and risk stratification based on baseline and on-treatment factors, including in particular the response to treatment. Those intolerant of treatment with UDCA or those with high-risk disease as evidenced by UDCA treatment failure (frequently reflected in trial and clinical practice as an alkaline phosphatase >1.67 × upper limit of normal and/or elevated bilirubin) should be considered for second-line therapy, of which OCA is the only currently licensed National Institute for Health and Care Excellence recommended agent. Follow-up of patients is life-long and must address treatment of the disease and management of associated symptoms.

    Read paper

  • Obeticholic Acid in Primary Biliary Cholangitis

    Obeticholic Acid in Primary Biliary Cholangitis

    Journal: New England Journal of Medicine 2016

    Author: Nevens et al. for the POISE Study Group*

    Summary: Nevens et al. (Aug. 18 issue)1 highlight the efficacy and safety of obeticholic acid in patients with primary biliary cholangitis. The inclusion of a trial with a short follow-up of 1 year for a disease with an estimated duration of one to two decades without intervention certainly dilutes the information that is needed for the analysis of clinically relevant outcomes. Appropriate criteria that define the treatment duration and response with new regimens for primary biliary cholangitis are unknown

    Read paper

  • Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study

    Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study

    Journal: Lancet. 2017

    Author: Hegade et al. 

    Summary: In patients with primary biliary cholangitis with pruritus, 14 days of ileal bile acid transporter inhibition by GSK2330672 was generally well tolerated without serious adverse events, and demonstrated efficacy in reducing pruritus severity. GSK2330672 has the potential to be a significant and novel advance for the treatment of pruritus in primary biliary cholangitis. Diarrhoea, the most common adverse event associated with GSK2330672 treatment, might limit the long-term use of this drug.

    Read paper